The Prevnar 20 approval comes a few weeks ahead of an FDA decision on Merck's V114, which was granted a priority review by the regulator in January for the prevention of IPD in adults.

Under the initiative, Buenos Aires-based Sinergium will produce Pfizer's Prevnar 20 in Argentina, with doses expected to be ready to roll out by 2026. In the meantime, countries across the ...

It covers 15 different pneumococcal serotypes – two more than Pfizer's current Prevnar 13 shot – and has been approved for use in patients aged 18 or over. Pfizer's updated 20-valent vaccine ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...

The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, ...

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...

For example, in April 2023, Pfizer Inc. received FDA approval for Prevnar 20 for the prevention of invasive pneumococcal disease IPD and otitis media. Regionally, North America was the largest ...

Pfizer PFE is a key player in the PCV vaccine space. PFE markets Prevnar 20, which is approved for the prevention of IPD caused by 20 serotypes in individuals aged six weeks and older. PFE also ...

VAX-31’s safety, tolerability, and immunogenicity are being assessed in this trial on healthy infants. Vaxcyte anticipat ...

Operator Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being ...